Abstract P6-04-05: GPR110 overexpression increases tumorigenic potential of HER2+ breast cancer cells
MV Trivedi(Beth Israel Deaconess Medical Center), Rachel Schiff(Baylor College of Medicine), Raksha R. Bhat(University of Houston), VA Narkar(Baylor College of Medicine), CK Osborne(Baylor College of Medicine), Mario Giuliano(Regione Campania), Pankaj Yadav(Baylor College of Medicine), Vijesh Kumar Yadav(Baylor College of Medicine), Charles Creighton(Baylor College of Medicine), Pavel Christiny(University of Houston), Ahmed Al-Rawi(University of Houston), Santosh K. Nanda(Baylor College of Medicine)
Cited by 0
Related Papers
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
|Cancer Research|2008|494
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
|Science|2011|440
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413